Opus Genetics Jumps After Early Gene Therapy Data Show Vision Gains in All 5 Patients

Low-dose OPGx-BEST1 improved vision in all 5 patients and looked safe. Opus plans a higher-dose readout in Q2 2027 and Phase 3 in 2027.